GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years and as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

Trust is earned

When immune globulin (IG) is the standard of care, health systems and providers trust GAMMAGARD LIQUID–for a reason. It's supported by a proven history of clinical use and an established safety profile.2,3

About GAMMAGARD LIQUID

A proven history of clinical use2

15 years of experience icon.

15 years of real-world experience4

Worldwide coverage icon.

120,108 patients2*

IVIG bag icon.

1,441,300 infusions2*

*Calculations based on units of GAMMAGARD LIQUID sold from 2006-2019, assuming an average utilization of 450 g/yr/patient.

  • No sucrose
  • No added sodium
  • No glucose or proline stabilizers
  • No added sugars
  • No added preservatives
  • Stabilized and buffered with glycine
Explore product characteristics

An established safety profile

The safety of GAMMAGARD LIQUID was evaluated in patients with Primary Immunodeficiency (PI) and in the largest clinical trial of Multifocal Motor Neuropathy (MMN) to date.3,6 Review important safety information, including contraindications and specific warnings and precautions, to consider when prescribing and monitoring patients treated with GAMMAGARD LIQUID.

Review safety information
Safety icon. GAMMAGARD LIQUID vials.

Access forms, codes, and additional resources to support your hospital or practice.

See resources
Primary Immunodeficiency icon.

Primary Immunodeficiency (PI)

GAMMAGARD LIQUID is indicated as replacement therapy for PI in adult and pediatric patients ≥2 years of age.

GAMMAGARD LIQUID can help PI patients and healthcare professionals feel at ease with a proven history of clinical use you can trust, in a comfortable environment.3

See PI information
Multifocal Motor Neuropathy icon.

Multifocal Motor Neuropathy (MMN)

GAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and disability in adult patients with MMN.

Healthcare professionals and patients rely on GAMMAGARD LIQUID, the first and only FDA-approved treatment for MMN.3

See MMN information